| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 23
Oral Abstracts HIV/HCV Co-Infection Tuesday, 4 - 6:15 pm Room 3000 |
| Moderators | Georg Lauer Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown, USA Margaret Ragni Magee-Womens Res Inst and Hemophilia Ctr of Western Pennsylvania and Univ of Pittsburgh Med Ctr, USA |
| 4:00 pm 110 | A Randomized, Controlled Trial of PEG-Interferon- R Chung*1, J Andersen2, P Volberding3, G Robbins1, T Liu2, K Sherman4, M Peters3, M Koziel5, B Alston6, D Colquhoun7, T Nevin8, G Harb9, C van der Horst10, and AIDS Clinical Trials Group A5071 Study Team 1Mass Gen. Hosp., Boston, MA, USA; 2Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Univ. of California, San Francisco, USA; 4Univ. of Cincinnati, OH, USA; 5Beth Israel Deaconess Hosp., Boston, MA, USA; 6DAIDS, NIAID, NIH, DHHS, Bethesda, MD, USA; 7DMC, FSTRF, Buffalo, NY, USA; 8Social and Sci. Systems, Inc., Rockville, MD, USA; 9Roche Labs., Nutley, NJ, USA; and 10Univ. of North Carolina at Chapel Hill, USA |
| 4:15 pm 111 | Relationships between Hepatitis C Virus-specific Immune Responses and Outcomes of Treatment with Interferon and Ribavirin in HIV/HCV Co-infection C Graham*1, A Wells1, T Liu2, K Sherman3, M Peters4, R Chung5, J Andersen2, M Koziel1, and for the ACTG A5071 Study Team 1Beth Israel Deaconess Med. Ctr. and Harvard Med. Sch., Boston, MA, USA; 2Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Univ. of Cincinnati, OH, USA; 4Univ. of California, San Francisco, USA; and 5Massachusetts Gen. Hosp. and Harvard Med. Sch., Boston, MA |
| 4:30 pm 112 | Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating Peginterferon- F J Torriani1, J Rockstroh2, M Rodriguez-Torres3, E Lissen4, J Gonzalez5, A Lazzarin6, G Carosi7, J Sasadeusz8, C Katlama9, J Montaner10, H Sette11, F Duff12, J DePamphilis12, U M Schrenk13, and D Dieterich*14 1Univ. of California, San Diego, USA; 2Univ. of Bonn, Germany; 3Fndn. de Investigación de Diego, Santurce, PR, USA; 4Virgen del Rocío Univ. Hosp., Seville, Spain; 5Hosp. La Paz, Madrid, Spain; 6San Raffaele Vita-Salute Univ., Milan, Italy; 7Univ. of Brescia, Italy; 8Royal Melbourne Hosp., Australia; 9Hosp. Pitié-Salpêtrière, Paris, France; 10Univ. of British Columbia, Vancouver, Canada; 11Inst. de Infectologia Emilio Ribas, Sao Paulo, Brazil; 12Roche, Nutley, NJ, USA; 13Roche, Basel, Switzerland; and 14Mt Sinai Sch. of Med., New York, NY, USA |
| 4:45 pm 113 | Intrahepatic T-cell Responses to Hepatitis C Virus in Patients Co-infected with HCV and HIV prior to anti-HCV Therapy N Alatrakchi*1, C S Graham1, K E Sherman2, and M J Koziel1 1Harvard Med. Sch. and Beth Israel Deaconess Med. Ctr., Boston, MA, USA and 2Univ. of Cincinnati, OH, USA |
| 5:00 pm 114 | Frequency of Functional HCV-specific CD8+ Cells Depends on Total CD4+ Counts in HIV-1/HCV Co-infection: Implications for Immune Reconstitution A Y Kim*1, K Ouchi1, R Draenert1, M M Addo1, M Lucas2, M A Boczanowski1, A G Wurcel1,3, B McGovern3,4, D Casson5, RT Chung5, P Klenerman2, B D Walker1, and G M Lauer1 1Partners AIDS Res. Ctr., Massachusetts Gen. Hosp., Charlestown, USA; 2Oxford Univ., UK; 3Lemuel Shattuck Hosp., Jamaica Plain, MA, USA; 4Tufts Med. Sch., Boston, MA, USA; and 5Massachusetts Gen. Hosp., Boston, USA |
| 5:15 pm 115 | Hemigenomic Analysis of Hepatitis C Sequence Variation in a Common-Source Outbreak in Relation to Predicted HLA Class I Epitopes S Ray*1, L Fanning2, X Wang1, D Netski1, and D Thomas1 1Johns Hopkins Univ. Sch. of Med., Baltimore, MD, USA and 2Cork Univ. Hosp., Ireland |
| 5:30 pm 116 | DNA Polymorphisms Affect Severity of Disease and Response to Therapy in Subjects Co-infected with HCV and HIV M Peters*1, J Anderson2, R Chung3, M Koziel4, K Sherman5, R Apple6, and ACTG 5071 team and NIAID – AIDS Clinical Trials Group, Bethesda, MD 1Univ. of California, San Francisco, USA; 2Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Harvard Med. Sch., Massachusetts Gen. Hosp., Boston, USA; 4Harvard Inst. of Med., Boston, MA, USA; 5Univ. of Cincinnati Med. Ctr., OH, USA; and 6Roche Molecular Systems, Alameda CA, USA |
| 5:45 pm 117LB | Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-Interferon- C Perronne*1, F Carrat2, F Bani-Sadr2, S Pol3, E Rosenthal4, F Lunel5, P Morand6, D Salmon7, G Pialoux8, G Raguin8, C Grillot-Courvalin9, P Cacoub10, and ANRS HC02-RIBAVIC study group 1CHU Raymond-Poincaré, Garches, France; 2CHU Saint-Antoine, INSERM, Paris, France; 3CHU Necker, Paris, France; 4CHU de l'Archet, Nice, France; 5CHU Hotel-Dieu, Angers, France; 6CHU Michalon, Grenoble, France; 7CHU Cochin, Paris, France; 8CHU Saint-Antoine, Paris, France; 9ANRS, Paris, France; and 10CHU Pitié-Salpétrière, Paris, France |
| 6:00 pm 118LB | HCV Resistance to Peg-Interferon/Ribavirin Therapy Is Associated with Increased Immune Activation in HIV/HCV Co-infected Patients R A Lempicki*1, J Yang1, G Dennis1, M McLaughlin2, C Koratich2, D Kleiner3, S Kottilil2, and M A Polis2 1SAIC-Frederick, Inc., MD, USA; 2NIAID, NIH, DHHS, Bethesda, MD, USA; and 3NCI, NIH, DHHS, Bethesda, MD, USA |